2025-05-14 REL RCSB INITIAL_RELEASE REPOSITORY INITIAL_RELEASE REPOSITORY INITIAL_RELEASE REPOSITORY INITIAL_RELEASE REPOSITORY INITIAL_RELEASE REPOSITORY INITIAL_RELEASE REPOSITORY EXPERIMENTAL_SUMMARY em_admin em_software _em_admin.last_update _em_software.name STRUCTURE_SUMMARY chem_comp_atom chem_comp_bond em_admin pdbx_entry_details pdbx_modification_feature _em_admin.last_update _pdbx_entry_details.has_protein_modification DATA_COLLECTION em_admin em_software _em_admin.last_update _em_software.name RCSB RCSB 2021-03-05 2021-09-22 2021-09-22 2025-05-14 Global Health Innovative Technology Fund RFP-HTLP-H2019-101 United States Australian Research Council (ARC) FL150100106 Australia Structure of human 20S proteasome with bound ML052. Hanssen E Xie SC Liu B Leis AP Morton CJ Metcalfe RD Tilley L Griffin MDW proteasome, plasmodium falciparum, malaria, drug, bortezomib, HYDROLASE Xie SC Metcalfe RD Mizutani H Puhalovich T Hanssen E Morton CJ Du Y Dogovski C Huang SC Ciavarri J Hales P Griffin RJ Cohen LH Chuang BC Wittlin S Deni I Yeo T Ward KE Barry DC Liu B Gillett DL Crespo-Fernandez BF Ottilie S Mittal N Churchyard A Ferguson D Aguiar ACC Guido RVC Baum J Hanson KK Winzeler EA Gamo FJ Fidock DA Baud D Parker MW Brand S Dick LR Griffin MDW Gould AE Tilley L Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proc.Natl.Acad.Sci.USA US 118 2021 34548400 doi:10.1073/pnas.2107213118 1091-6490 0040 PNASA6 7lxv FULLOVERLAP Homo sapiens 20S proteasome complexed with ML052 Homo sapiens 20S proteasome complexed with ML052 0 1 2 3 4 5 6 7 8 9 10 12 13 14 Plasmodium falciparum 3D7 0.7 Proteasome subunit alpha type-2 Homo sapiens 0.025927534999999998 2 LEVO MAERGYSFSLTTFSPSGKLVQIEYALAAVAGGAPSVGIKAANGVVLATEKKQKSILYDERSVHKVEPITKHIGLVYSGMG PDYRVLVHRARKLAQQYYLVYQEPIPTAQLVQRVASVMQEYTQSGGVRPFGVSLLICGWNEGRPYLFQSDPSGAYFAWKA TAMGKNYVNGKTFLEKRYNEDLELEDAIHTAILTLKESFEGQMTEDNIEVGICNEAGFRRLTPTEVKDYLAAIA P25787 3.4.25.1 Proteasome subunit alpha type-4 Homo sapiens 0.029525842 2 LEVO MSRRYDSRTTIFSPEGRLYQVEYAMEAIGHAGTCLGILANDGVLLAAERRNIHKLLDEVFFSEKIYKLNEDMACSVAGIT SDANVLTNELRLIAQRYLLQYQEPIPCEQLVTALCDIKQAYTQFGGKRPFGVSLLYIGWDKHYGFQLYQSDPSGNYGGWK ATCIGNNSAAAVSMLKQDYKEGEMTLKSALALAIKVLNKTMDVSKLSAEKVEIATLTRENGKTVIRVLKQKEVEQLIKKH EEEEAKAEREKKEKEQKEKDK P25789 3.4.25.1 Proteasome subunit alpha type-7 Homo sapiens 0.027929891 2 LEVO MSYDRAITVFSPDGHLFQVEYAQEAVKKGSTAVGVRGRDIVVLGVEKKSVAKLQDERTVRKICALDDNVCMAFAGLTADA RIVINRARVECQSHRLTVEDPVTVEYITRYIASLKQRYTQSNGRRPFGISALIVGFDFDGTPRLYQTDPSGTYHAWKANA IGRGAKSVREFLEKNYTDEAIETDDLTIKLVIKALLEVVQSGGKNIELAVMRRDQSLKILNPEEIEKYVAEIEKEKEENE KKKQKKAS O14818 3.4.25.1 Proteasome subunit alpha type-5 Homo sapiens 0.026435977 2 LEVO MFLTRSEYDRGVNTFSPEGRLFQVEYAIEAIKLGSTAIGIQTSEGVCLAVEKRITSPLMEPSSIEKIVEIDAHIGCAMSG LIADAKTLIDKARVETQNHWFTYNETMTVESVTQAVSNLALQFGEEDADPGAMSRPFGVALLFGGVDEKGPQLFHMDPSG TFVQCDARAIGSASEGAQSSLQEVYHKSMTLKEAIKSSLIILKQVMEEKLNATNIELATVQPGQNFHMFTKEELEEVIKD I P28066 3.4.25.1 Proteasome subunit alpha type-1 Homo sapiens 0.029595627 2 LEVO MFRNQYDNDVTVWSPQGRIHQIEYAMEAVKQGSATVGLKSKTHAVLVALKRAQSELAAHQKKILHVDNHIGISIAGLTAD ARLLCNFMRQECLDSRFVFDRPLPVSRLVSLIGSKTQIPTQRYGRRPYGVGLLIAGYDDMGPHIFQTCPSANYFDCRAMS IGARSQSARTYLERHMSEFMECNLNELVKHGLRALRETLPAEQDLTTKNVSIGIVGKDLEFTIYDDDDVSPFLEGLEERP QRKAQPAQPADEPAEKADEPMEH P25786 3.4.25.1 Proteasome subunit alpha type-3 Homo sapiens 0.028469252 2 LEVO MSSIGTGYDLSASTFSPDGRVFQVEYAMKAVENSSTAIGIRCKDGVVFGVEKLVLSKLYEEGSNKRLFNVDRHVGMAVAG LLADARSLADIAREEASNFRSNFGYNIPLKHLADRVAMYVHAYTLYSAVRPFGCSFMLGSYSVNDGAQLYMIDPSGVSYG YWGCAIGKARQAAKTEIEKLQMKEMTCRDIVKEVAKIIYIVHDEVKDKAFELELSWVGELTNGRHEIVPKDIREEAEKYA KESLKEEDESDDDNM P25788 3.4.25.1 Proteasome subunit alpha type-6 Homo sapiens 0.027432459 2 LEVO MSRGSSAGFDRHITIFSPEGRLYQVEYAFKAINQGGLTSVAVRGKDCAVIVTQKKVPDKLLDSSTVTHLFKITENIGCVM TGMTADSRSQVQRARYEAANWKYKYGYEIPVDMLCKRIADISQVYTQNAEMRPLGCCMILIGIDEEQGPQVYKCDPAGYY CGFKATAAGVKQTESTSFLEKKVKKKFDWTFEQTVETAITCLSTVLSIDFKPSEIEVGVVTVENPKFRILTEAEIDAHLV ALAERD P60900 3.4.25.1 Proteasome subunit beta type-7 Homo sapiens 0.025321979999999997 2 LEVO TTIAGVVYKDGIVLGADTRATEGMVVADKNCSKIHFISPNIYCCGAGTAADTDMTTQLISSNLELHSLSTGRLPRVVTAN RMLKQMLFRYQGYIGAALVLGGVDVTGPHLYSIYPHGSTDKLPYVTMGSGSLAAMAVFEDKFRPDMEEEEAKNLVSEAIA AGIFNDLGSGSNIDLCVISKNKLDFLRPYTVPNKKGTRLGRYRCEKGTTAVLTEKITPLEIEVLEETVQTMDTS Q99436 3.4.25.1 Proteasome subunit beta type-3 Homo sapiens 0.022972896 2 LEVO MSIMSYNGGAVMAMKGKNCVAIAADRRFGIQAQMVTTDFQKIFPMGDRLYIGLAGLATDVQTVAQRLKFRLNLYELKEGR QIKPYTLMSMVANLLYEKRFGPYYTEPVIAGLDPKTFKPFICSLDLIGCPMVTDDFVVSGTCAEQMYGMCESLWEPNMDP DHLFETISQAMLNAVDRDAVSGMGVIVHIIEKDKITTRTLKARMD P49720 3.4.25.1 Proteasome subunit beta type-2 Homo sapiens 0.022864277 2 LEVO MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSEKILLLCVGEAGDTVQFAEYIQKNVQLYKMRNGYELSPTAA ANFTRRNLADCLRSRTPYHVNLLLAGYDEHEGPALYYMDYLAALAKAPFAAHGYGAFLTLSILDRYYTPTISRERAVELL RKCLEELQKRFILNLPTFSVRIIDKNGIHDLDNISFPKQGS P49721 3.4.25.1 Proteasome subunit beta type-5 Homo sapiens 0.022484368999999997 2 LEVO TTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWERLLARQCRIYELRNKERISVAAAS KLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDSEGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAI YQATYRDAYSGGAVNLYHVREDGWIRVSSDNVADLHEKYSGSTP P28074 3.4.25.1 Proteasome subunit beta type-1 Homo sapiens 0.023578986 2 LEVO RFSPYVFNGGTILAIAGEDFAIVASDTRLSEGFSIHTRDSPKCYKLTDKTVIGCSGFHGDCLTLTKIIEARLKMYKHSNN KAMTTGAIAAMLSTILYSRRFFPYYVYNIIGGLDEEGKGAVYSFDPVGSYQRDSFKAGGSASAMLQPLLDNQVGFKNMQN VEHVPLSLDRAMRLVKDVFISAAERDVYTGDALRICIVTKEGIREETVSLRKD P20618 3.4.25.1 Proteasome subunit beta type-4 Homo sapiens 0.02441474 2 LEVO TQNPMVTGTSVLGVKFEGGVVIAADMLGSYGSLARFRNISRIMRVNNSTMLGASGDYADFQYLKQVLGQMVIDEELLGDG HSYSPRAIHSWLTRAMYSRRSKMNPLWNTMVIGGYADGESFLGYVDMLGVAYEAPSLATGYGAYLAQPLLREVLEKQPVL SQTEARDLVERCMRVLYYRDARSYNRFQIATVTEKGVEIEGPLSTETNWDIAHMISGFE P28070 3.4.25.1 Proteasome subunit beta type-6 Homo sapiens 0.021921835999999997 2 LEVO TTIMAVQFDGGVVLGADSRTTTGSYIANRVTDKLTPIHDRIFCCRSGSAADTQAVADAVTYQLGFHSIELNEPPLVHTAA SLFKEMCYRYREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREGMTKEECLQFTANAL ALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVATLPPA P28072 3.4.25.1 N-[(1R)-2-([1,1'-biphenyl]-4-yl)-1-boronoethyl]-1-methyl-L-prolinamide 0.000352235 2 YHD singleParticle particle 7.4 Quantifoil R1.2/1.3 GOLD 300 GOLD ETHANE 100 295 FEI VITROBOT MARK III FEI TALOS ARCTICA FLOOD BEAM BRIGHT FIELD FIELD EMISSION GUN 200 50.0 2.7 GATAN K2 SUMMIT (4k x 4k) SUPER-RESOLUTION 50.0 1 RELION 3 wraper for motioncorr2, particle polishing MotionCorr2 2 motion correction cryoSPARC 2.15 particle picking, 2D classes, 3D classes, refinements PHASE FLIPPING AND AMPLITUDE CORRECTION 3.4 FSC 0.143 CUT-OFF 192367 MAXIMUM LIKELIHOOD MAXIMUM LIKELIHOOD emd_23576.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 300 300 300 0 0 0 300 300 300 392.99997 392.99997 392.99997 90.0 90.0 90.0 Z Y X -20.277372 28.628477 0.000000000001379 1.0 1.31 1.31 1.31 5.0 AUTHOR sharpened map used for refinement emd_23576_additional_1.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 300 300 300 0 0 0 300 300 300 392.99997 392.99997 392.99997 90.0 90.0 90.0 X Y Z -1.5403513 3.5750096 -0.0018474255 0.14787225 1.31 1.31 1.31 AUTHOR initial unsharpened output map from Cryosparc emd_23576_half_map_2.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 300 300 300 0 0 0 300 300 300 392.99997 392.99997 392.99997 90.0 90.0 90.0 X Y Z -2.3383746 4.0596523 0.0042259963 0.31283852 1.31 1.31 1.31 AUTHOR half-volume 2 emd_23576_half_map_1.map.gz 1 IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) 300 300 300 0 0 0 300 300 300 392.99997 392.99997 392.99997 90.0 90.0 90.0 X Y Z -2.0648293 4.295536 0.00429262 0.31322852 1.31 1.31 1.31 AUTHOR half-volume 1